The company in question is, AbbVie Inc. (NYSE:ABBV) currently with a stock price of 66.17 (-0.56% today). The market cap for AbbVie Inc. is 108726.36, and is in the sector Healthcare, and Drug Manufacturers – Major industry. The target price for AbbVie Inc. is 70.61. Currently AbbVie Inc. is trading with a P/E of 19.08, and a forward P/E of 11.75. Average volume for AbbVie Inc. is 8868.1 and so far today it is 2180574.
Performance in the last year for AbbVie Inc. has been -0.18%. For EPS growth, AbbVie Inc. has seen a growth of 185.20%, and is looking to grow in the next year to 18.08%. More long term stats show that EPS growth has been 3.50% over the last five years and could be 16.28% for the next five years. AbbVie Inc. has seen sales growth quarter over quarter at 17.80%, with EPS growth quarter over quarter at 17.90%. The 20-day simple moving average is 5.69%, with the 200-day simple moving average coming to 13.78%.
Since the IPO date for AbbVie Inc. on the 1/2/2013, AbbVie Inc. has seen performance year to date to be 15.60%. With AbbVie Inc. trading at 66.17, the dividend yield is 3.43%, and the EPS is 3.49.
So could AbbVie Inc., be undervalued? Well as said before P/E is 19.08. The PEG is 1.17, P/S is 4.39 and the P/B is at 23.18. The P/cash is *TBA, with P/free cash flow at *TBA.
AbbVie Inc. ability to deal with debt shows that the current ratio is *TBA, and the quick ratio is *TBA. This is with long term debt/equity at *TBA, and total debt/equity at *TBA.
In terms of margins, AbbVie Inc. has a gross margin of 78.60%, an operating margin of 35.00% and a profit margin of 23.10%.Payout ratio for AbbVie Inc. is 47.10%. Return on assets come to *TBA with return on investment coming to 16.90%.
Insider ownership for AbbVie Inc., is at 0.10% and institutional ownership comes to 70.20%. Outstanding shares are at 1634. While shares float is 1616.02. The float short is currently 3.75%, and short ratio is 6.83.